Aprea Therapeutics (APRE) H.C. Wainwright 27th Annual Global Investment Conference summary

Pipeline overview and strategic focus

• Focused on precision medicine and synthetic lethality with a pipeline including ATR and WEE1 inhibitors, a legacy p53 reactivator, and undisclosed targets to be revealed later in the year.

• Strong emphasis on intellectual property protection for all programs, with disclosure of new targets planned after securing IP.

• Management and board bring extensive drug development experience, supporting ongoing and future clinical activities.

Clinical development progress

• WEE1 inhibitor APR-1051 IND filed and cleared in 2024; first patient enrolled and dose escalation ongoing with FDA-approved higher dosing.

• Early clinical data show stable disease and minor tumor reductions at subtherapeutic doses, with increased stable disease at higher doses.

• ATR inhibitor program adjusted to BID dosing due to pharmacokinetics, with ongoing dose escalation and early signs of tumor shrinkage.

Translational and biomarker-driven approach

• Preclinical models show strong translation to clinical outcomes, especially in biomarker-selected populations such as FBXW7 and HPV-positive cancers.

• Collaboration with MD Anderson supports biomarker-driven trials and combination therapy research.

• Combination therapies demonstrate synergistic effects and sustained tumor suppression in preclinical studies.